Although the novel use of PSMA as a biomarker in non-prostatic cancer in human patients has been studied previously, the applications of PSMA as a vascular targeted agent in these murine breast cancer models requires further research [32, 33]. Here, FOLH1 is linked to prostate carcinoma.